Polymer-Drug Conjugate, a Potential Therapeutic to Combat Breast and Lung Cancer.

Sibusiso Alven,Buhle Buyana,Xhamla Nqoro,Blessing A. Aderibigbe

doi:10.3390/pharmaceutics12050406

Sibusiso Alven, Buhle Buyana + Show 2 more

Open Access

https://doi.org/10.3390/pharmaceutics12050406

Copy DOI

Journal: Pharmaceutics	Publication Date: Apr 29, 2020
Citations: 66	License type: CC BY 4.0

Affiliation: University of Fort Hare

Abstract

Cancer is a chronic disease that is responsible for the high death rate, globally. The administration of anticancer drugs is one crucial approach that is employed for the treatment of cancer, although its therapeutic status is not presently satisfactory. The anticancer drugs are limited pharmacologically, resulting from the serious side effects, which could be life-threatening. Polymer drug conjugates, nano-based drug delivery systems can be utilized to protect normal body tissues from the adverse side effects of anticancer drugs and also to overcome drug resistance. They transport therapeutic agents to the target cell/tissue. This review article is based on the therapeutic outcomes of polymer-drug conjugates against breast and lung cancer.

Highlights

Cancer is a chronic disease that leads to great mortality around the world and cancer cases are rising continuously [1]
The findings suggest that the administration of polymer-drug formulations intraductally can prolong ductal retention, resulting in reduced toxicity and enhanced sustained therapeutic outcomes [116]
The PAMAM-platinum conjugate displayed a survival rate at a minimum of 40.67% to a maximum of 67.45%, while the conjugate incorporated with both drugs displayed improved survival rate at a minimum of 55.47 to a maximum of 81.13% [118]. These findings revealed the potential of combining anticancer drugs with other therapeutic agents that are not anticancer agents using a polymer-based drug delivery system

Summary

Introduction

Cancer is a chronic disease that leads to great mortality around the world and cancer cases are rising continuously [1]. Several research reports of polymer-drug conjugates designed for the treatment of breast cancer displayed unique features, such as high cytotoxic effects against the breast cancer cell lines [111,112], suitable for the combination of two anticancer drugs, resulting in synergistic effects [112,113,115,121,124,125], high selectivity towards cancer microenvironment, followed by tumor cell death and increased the survival rate in vivo [115], extended blood circulation [122], extended half-life [116], good stability [124,125], and improved water solubility of the incorporated drug [117]. The route of administration of the conjugates, such as intraductal administration, has prolonged the ductal retention of the conjugates [116]

Polymer-Anticancer Drug Conjugates for Lung Cancer Treatment

Findings

Conclusions